Patents Examined by Kimberly Ballard
  • Antibodies against BACE1 and use thereof for neural disease immunotherapy
    Patent number: 10882920
    Abstract: The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: January 5, 2021
    Assignees: Genentech, Inc., Adimab LLC
    Inventors: Yichin Liu, Jasvinder Atwal, Cecilia Pui Chi Chiu, Ryan J. Watts, Yan Wu, Eric Krauland, Michael Feldhaus
  • Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
    Patent number: 10882902
    Abstract: Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: January 5, 2021
    Assignee: Neurimmune Holding AG
    Inventors: Jan Grimm, Fabrice Heitz, Feng Chen, Ioana Combaluzier
  • Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
    Patent number: 10874725
    Abstract: A treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 29, 2020
    Assignee: New York University
    Inventors: Karsten Henco, Roger Nitsch, Jan Grimm, Anja Zeller, Marcel Maier
  • Method for inducing differentiation of neural stem cells using patterned hydrogel
    Patent number: 10870831
    Abstract: The present invention provides a method for inducing differentiation of neural stem cells. The present invention provides optimized differentiation conditions of neural stem cells into neurons using a patterned hydrogel.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 22, 2020
    Assignee: SOGANG UNIVERSITY RESEARCH FOUNDATION
    Inventors: Bong Geun Chung, Jong Min Lee, Joo Yoon Moon, Tae Hyeon Kim, Daniel Christian Ahrberg
  • Compositions and methods for modulating neuronal excitability and motor behavior
    Patent number: 10870853
    Abstract: The invention is directed to compositions and methods for treating or reducing the likelihood of the development of epilepsy in an individual. The method comprises administering to the central nervous system of an individual in need of such treatment a therapeutically effective amount of an agent capable of increasing the expression and/or activity of miR-128.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: December 22, 2020
    Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE ROCKEFELLER UNIVERSITY
    Inventors: Anne Schaefer, Paul Greengard
  • Methods for treating Alzheimer's disease
    Patent number: 10842871
    Abstract: A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: November 24, 2020
    Assignee: Biogen International Neuroscience GmbH
    Inventors: James L. Ferrero, Leslie Lugene Williams, Jeffrey Joseph Sevigny
  • Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same
    Patent number: 10836814
    Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 17, 2020
    Assignees: YOKOHAMA CITY UNIVERSITY, CHIOME BEOSCIENCE INC.
    Inventors: Yoshio Goshima, Fumio Nakamura, Naoya Yamashita, Hidetaka Seo, Shuichi Hashimoto, Koji Murakami, Naoki Takahashi, Yukie Sasakura
  • Peptide for preventing hearing loss, and composition comprising same
    Patent number: 10835582
    Abstract: The present invention relates to a pharmaceutical composition for preventing and treating hearing loss. More particularly, the present invention relates to a composition including a telomerase-derived peptide, the composition being effective in the treatment and prevention of hearing loss due to an ototoxic drug. A peptide having a sequence of SEQ ID NO: 1, a peptide having 80% or more sequence homology to the sequence, or a fragment thereof, according to the present invention, has an excellent effect in the treatment and prevention of hearing loss due to an ototoxic drug.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: November 17, 2020
    Assignee: GemVaX & KAEL CO. LTD.
    Inventor: Sang Jae Kim
  • Therapeutic agents for neurological and psychiatric disorders
    Patent number: 10829528
    Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein a (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 10, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Joris De Wit, Heather Rice, Bart De Strooper
  • Anti-tau antibodies and uses thereof
    Patent number: 10829547
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 10, 2020
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Triglyceride otic formulations and uses thereof
    Patent number: 10821185
    Abstract: Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from medium chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 3, 2020
    Assignee: Otonomy Inc.
    Inventors: Robert Savel, Zhanpeng Zhang, Scott Coleman, Fabrice Piu, Hong Qi
  • Immunoassay standards and measurement of tau using intra-assay calibration standards
    Patent number: 10823739
    Abstract: The present invention provides novel peptides, compositions, and methods for creating quantitative novel compositions, as well as methods for creating quantitative standards to calibrate analytes. These peptides, compositions, and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers (e.g., Tau). Also provided are kits comprising the peptides or compositions described herein, for use in assays (e.g., sandwich immunoassays).
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: November 3, 2020
    Assignee: SALADAX BIOMEDICAL
    Inventors: Paul Rhyne, Adam J. Simon, Flora Berisha, Robert John Neely, Christopher J. Spedaliere, Claudio Mapelli
  • Methods and compositions for treating neurodegenerative and neuroinflammatory conditions
    Patent number: 10813979
    Abstract: Methods, compositions, and kits for diagnosing or treating neurodegenerative or neuroinflammatory conditions are provided. Also provided are methods for identifying modulators of neurodegenerative or neuroinflammatory conditions.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: October 27, 2020
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Kit Yu Fu, Foo Yew Liew, Nancy Yuk-Yu Ip
  • Method for detecting GABAA receptor autoantibodies
    Patent number: 10802019
    Abstract: The invention relates to methods of determining whether or not an individual has or is likely to develop a neurological disease and related methods and kits.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 13, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Angela Vincent, Philippa Pettingill, Patrick Waters
  • Anti-Siglec-9 antibodies and methods of use thereof
    Patent number: 10800844
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 13, 2020
    Assignee: ALECTOR LLC
    Inventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
  • Cardiac neural crest cells and methods of use thereof
    Patent number: 10786536
    Abstract: Cardiac neural crest cells and methods for making and using the same to effect cardiac injury is described herein.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: September 29, 2020
    Assignee: VESTION, INC.
    Inventors: Konstantinos E. Chatzistergos, Joshua M. Hare
  • Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
    Patent number: 10786557
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 29, 2020
    Assignee: SHIRE VIROPHARMA LLC
    Inventors: Colin Broom, Jeffrey Dayno
  • Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
    Patent number: 10781421
    Abstract: The present invention pertains to a method for the generation of neurotoxin-sensitive, neuronal differentiated cells comprising the steps of: a) cultivating tumor cells which are able to differentiate into neuronal cells in a culture medium under conditions and for a time which primes said tumor cells for neuronal differentiation; and b) cultivating the tumor cells primed for neuronal differentiation of a) in a differentiation medium having an osmolality of 100 to 270 mOsm/kg, and comprising (i) B27 supplement and/or (ii) N2 supplement, for at least 3 days, thereby obtaining neurotoxin-sensitive, neuronal differentiated cells. The invention further relates to neurotoxin-sensitive, neuronal differentiated cells obtainable by the method of the invention.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 22, 2020
    Assignee: MERE PHARMA GmbH & CO. KGaA
    Inventors: Karl-Heinz Eisele, Kai Harting
  • Method for producing cerebellar progenitor tissue
    Patent number: 10781420
    Abstract: The present invention provides a method for producing a human cell aggregate containing a midbrain-hindbrain boundary neural progenitor tissue, including subjecting an aggregate of human pluripotent stem cells to suspension culturing in a serum-free medium containing insulin, and treating, in the suspension culturing, the aggregate of human pluripotent stem cells or a human cell aggregate derived therefrom with a ROCK inhibitor, a TGF? signal inhibitor, and a first fibroblast growth factor. Furthermore, the human cell aggregate containing the midbrain-hindbrain boundary neural progenitor tissue is subjected to suspension culturing in a serum-free medium to induce formation of a neuroepithelial structure by neural progenitor in the neural progenitor tissue, whereby the human cell aggregate containing the cerebellar plate tissue can be obtained.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 22, 2020
    Assignees: RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Yoshiki Sasai, Keiko Muguruma
  • Ameliorating nervous systems disorders
    Patent number: 10780131
    Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla